Sermorelin
Overview
A synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates the pituitary to produce and release growth hormone through the natural GHRH receptor pathway, preserving the hypothalamic-pituitary feedback axis. It maintains physiological pulsatile GH secretion patterns.
Key Research Findings
FDA-approved for diagnostic evaluation and treatment of growth hormone deficiency in children. Clinical studies demonstrated increases in GH secretion, lean body mass, and improvements in body composition. Shown to improve sleep quality through enhanced slow-wave sleep.
Subcutaneous injection
FDA Approved
Interested in Sermorelin?
Find a verified provider experienced with Sermorelin protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Sermorelin ProviderRelated Peptides
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days. CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.
Ipamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH release. Unlike other GH secretagogues, ipamorelin does not significantly affect ACTH, cortisol, or prolactin levels, making it one of the most specific GH-releasing peptides. It works synergistically with GHRH analogs like CJC-1295.
Tesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways. It is the only FDA-approved treatment for HIV-associated lipodystrophy.
PT-141 (Bremelanotide / Vyleesi)
FDA ApprovedA synthetic cyclic heptapeptide melanocortin receptor agonist that activates MC3R and MC4R in the central nervous system. Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, PT-141 works centrally through hypothalamic melanocortin pathways that modulate sexual arousal and desire. It is a metabolite of Melanotan II without significant melanogenic activity.